Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 / Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04947254 | Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 23, 2026 |
| clinicaltrials |
| NCT06533644 | A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 91 | Syncromune, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03675893 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07110038 | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma | recruiting | Phase 2 | 25 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05071937 | ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer | recruiting | Phase 2 | 33 | Alexander B Olawaiye, MDOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05538091 | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | recruiting | Phase 2 | 48 | Ronald BuckanovichOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06922318 | The COSMYC Trial (COmbined Suppression of MYC) | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07407582 | Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) | recruiting | Phase 1 / Phase 2 | 25 | University of ArizonaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07635238 | A Study of Lower Dose Radiation Therapy for People With Prostate Cancer | recruiting | Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04055649 | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | recruiting | Phase 2 | 62 | Ira WinerOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05790213 | Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation | recruiting | Phase 2 | 57 | University of ChicagoOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06392295 | PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer(OCEAN) | recruiting | Phase 2 | 34 | University of MiamiOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07027124 | Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer | recruiting | Phase 2 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07424664 | A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer | recruiting | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05422911 | Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | recruiting | Phase 2 | 192 | Sun Pharmaceutical Industries LimitedINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06434350 | Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) | recruiting | Phase 1 / Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | recruiting | Phase 2 | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05873192 | Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07022470 | Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT). | recruiting | Phase 2 | 41 | Stanford UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07441889 | HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646145 | Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 2 | 30 | Shanxi Province Cancer HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646301 | Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer(QUARTZ-CC) | recruiting | Phase 2 | 103 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr(DURANCE) | recruiting | Phase 1 / Phase 2 | 52 | University College, LondonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06675357 | Using FAPI PET/MRI to Evaluate Prostate Cancer | recruiting | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07048457 | Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma(CONSOLIdATE-1) | recruiting | Phase 2 | 32 | Yale UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 178 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07037004 | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery | recruiting | Phase 2 | 62 | City of Hope Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06104618 | Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis | recruiting | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06402357 | High Intensity Focused Ultrasound in Prostate Cancer | recruiting | Phase 2 | 25 | University of FloridaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07107334 | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05168618 | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer(AtezoCab) | recruiting | Phase 2 | 33 | University of UtahOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05916196 | [18F]FES PET/.CT in Uterine Cancer | recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06499870 | Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial | recruiting | Phase 2 | 50 | Sean SachdevOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03821246 | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | recruiting | Phase 2 | 68 | David OhOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05247268 | Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06609005 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 84 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT06783348 | Radiopharmaceutical Treatment of Advanced Kidney Cancer(RENALUT) | recruiting | Phase 2 | 48 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06914297 | TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC | recruiting | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2026source: clinicaltrials